Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model.
Morvarid KabirFrancesca PiccininiJay PorterDarko StefanovskiRebecca L PaszkiewiczFrancesca PiccininiOrison O WoolcottHsiuChiung YangV Sashi GopaulLinsey StilesCathryn M KolkaPublished in: Obesity (Silver Spring, Md.) (2023)
For the first time, to our knowledge, we identify mechanisms by which DAPA enhances adipose tissue function in regulating energy homeostasis in an insulin-resistant canine model.